Seattle Genetics and Agensys Announce Co-Development of Antibody-Drug Conjugate

News   Jul 01, 2013

 
Seattle Genetics and Agensys Announce Co-Development of Antibody-Drug Conjugate
 
 
 

RELATED ARTICLES

Two Studies Provide Significant Hope in the Fight Against Antibiotic Resistance

News

Two recent studies led by the University of Bristol provide significant new hope in the fight against antibiotic resistance.

READ MORE

Quotient Clinical Signs Cocrystal Agreement with Nuformix

News

Partnership to evaluate cocrystal formulations using translational pharmaceutics.

READ MORE

Gilead Company Wins FDA Approval for CAR T Cancer Therapy for Treatment of Adult Lymphoma

News

Kite’s Yescarta™ (axicabtagene ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE